RU2769050C1 - Кристаллическая форма и солевая форма соединения пиридоимидазола и соответствующий способ получения - Google Patents

Кристаллическая форма и солевая форма соединения пиридоимидазола и соответствующий способ получения Download PDF

Info

Publication number
RU2769050C1
RU2769050C1 RU2020131044A RU2020131044A RU2769050C1 RU 2769050 C1 RU2769050 C1 RU 2769050C1 RU 2020131044 A RU2020131044 A RU 2020131044A RU 2020131044 A RU2020131044 A RU 2020131044A RU 2769050 C1 RU2769050 C1 RU 2769050C1
Authority
RU
Russia
Prior art keywords
compound
crystalline form
curve
ray powder
pattern
Prior art date
Application number
RU2020131044A
Other languages
English (en)
Russian (ru)
Inventor
Цзиань СЮН
Сяосинь ЧЭН
Цзинцзин Ван
Чжовэй ЛЮ
Кэвин Х ЧЭН
Чэну ЛЮ
Чэн СЕ
Чаофэн ЛУН
Пэн ЛИ
Цзянь Ли
Шухуэй Чэнь
Original Assignee
Гуандун Рэйновент Байотек Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Гуандун Рэйновент Байотек Ко., Лтд. filed Critical Гуандун Рэйновент Байотек Ко., Лтд.
Application granted granted Critical
Publication of RU2769050C1 publication Critical patent/RU2769050C1/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/01—Sulfonic acids
    • C07C309/28—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C309/29—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings
    • C07C309/30—Sulfonic acids having sulfo groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton of non-condensed six-membered aromatic rings of six-membered aromatic rings substituted by alkyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
RU2020131044A 2018-03-05 2019-03-05 Кристаллическая форма и солевая форма соединения пиридоимидазола и соответствующий способ получения RU2769050C1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810180641.8 2018-03-05
CN201810180641 2018-03-05
PCT/CN2019/076916 WO2019170067A1 (zh) 2018-03-05 2019-03-05 一种吡啶并咪唑类化合物的晶型、盐型及其制备方法

Publications (1)

Publication Number Publication Date
RU2769050C1 true RU2769050C1 (ru) 2022-03-28

Family

ID=67846865

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020131044A RU2769050C1 (ru) 2018-03-05 2019-03-05 Кристаллическая форма и солевая форма соединения пиридоимидазола и соответствующий способ получения

Country Status (11)

Country Link
US (1) US11535613B2 (enExample)
EP (1) EP3763713A4 (enExample)
JP (1) JP7031002B2 (enExample)
KR (1) KR102484804B1 (enExample)
CN (1) CN111819177B (enExample)
AU (1) AU2019230497B2 (enExample)
CA (1) CA3092315C (enExample)
NZ (1) NZ767352A (enExample)
RU (1) RU2769050C1 (enExample)
TW (1) TWI794433B (enExample)
WO (1) WO2019170067A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX394277B (es) * 2016-09-05 2025-03-24 Guangdong Raynovent Biotech Co Ltd Derivados de pirimidina contra virus de la influenza
CN114127068B (zh) * 2019-07-22 2024-05-28 广东众生睿创生物科技有限公司 嘧啶衍生物的优势盐型及其晶型
CN114502150B (zh) * 2019-09-10 2023-03-24 广东众生睿创生物科技有限公司 一种用于治疗病毒性感冒的药物组合物及其制剂
CN113116899B (zh) * 2020-03-06 2022-12-20 广东众生睿创生物科技有限公司 一种用于治疗流感的药物组合物及含有该药物组合物的制剂
WO2022089261A1 (zh) * 2020-10-29 2022-05-05 广东众生睿创生物科技有限公司 一种嘧啶衍生物的晶型及其制备方法
EP4286386A4 (en) * 2021-02-03 2025-03-12 Ocumension Therapeutics (Suzhou) Co., Ltd. Salt form and crystal form of a pyrazole-substituted imidazo[1,2-a]quinoxaline derivative
JP2024509939A (ja) * 2021-03-11 2024-03-05 シャンハイ ジェミンケア ファーマシューティカル カンパニー，リミティド ピリジン窒素酸化物の結晶形態およびその使用
WO2025237212A1 (zh) * 2024-05-11 2025-11-20 广东众生睿创生物科技有限公司 一种嘧啶衍生物葡甲胺盐及其晶型

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012083117A1 (en) * 2010-12-16 2012-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
EA201270032A1 (ru) * 2009-06-17 2012-07-30 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
WO2016020526A1 (en) * 2014-08-08 2016-02-11 Janssen Sciences Ireland Uc Indoles for use in influenza virus infection
WO2017133670A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX341342B (es) * 2011-01-14 2016-08-17 Vertex Pharma Formas solidas del inhibidor de girasa (r)-1-etil-3-[6-fluoro-5-[2 -(1-hidroxi-1-metil-etil) pirimidin-5-il]-7-(tetrahidrofuran-2-il) -1h-benzimidazol-2-il]urea.
EP3362451B1 (en) 2015-12-09 2023-04-12 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
WO2017133667A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyrimidine and pyridine derivatives and use in treatment, amelioration or prevention of influenza thereof
JP7129339B2 (ja) * 2016-03-07 2022-09-01 ハイテック パワー，インコーポレーテッド 内燃エンジン用第２燃料を発生させかつ分配する方法
MX394277B (es) * 2016-09-05 2025-03-24 Guangdong Raynovent Biotech Co Ltd Derivados de pirimidina contra virus de la influenza

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201270032A1 (ru) * 2009-06-17 2012-07-30 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
WO2012083117A1 (en) * 2010-12-16 2012-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2016020526A1 (en) * 2014-08-08 2016-02-11 Janssen Sciences Ireland Uc Indoles for use in influenza virus infection
WO2017133670A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza

Also Published As

Publication number Publication date
AU2019230497A1 (en) 2020-09-17
EP3763713A1 (en) 2021-01-13
KR102484804B1 (ko) 2023-01-04
JP7031002B2 (ja) 2022-03-07
TWI794433B (zh) 2023-03-01
US11535613B2 (en) 2022-12-27
CN111819177B (zh) 2022-03-04
NZ767352A (en) 2023-05-26
WO2019170067A1 (zh) 2019-09-12
CA3092315A1 (en) 2019-09-12
CN111819177A (zh) 2020-10-23
EP3763713A4 (en) 2021-11-24
KR20200124710A (ko) 2020-11-03
AU2019230497B2 (en) 2021-08-05
CA3092315C (en) 2023-08-29
TW201938558A (zh) 2019-10-01
JP2021514967A (ja) 2021-06-17
US20200407354A1 (en) 2020-12-31

Similar Documents

Publication Publication Date Title
TWI794433B (zh) 吡啶并吡唑類化合物的晶型、鹽型及其製備方法
US12024494B2 (en) Salt of LSD1 inhibitor and a polymorph thereof
KR102064807B1 (ko) 바이러스 감염을 치료하기 위한 피페리디노-피리미딘 유도체
HUP0300908A2 (hu) 3-Nitrogén-6,7-dioxigén-szteroidok és alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
JP6704422B2 (ja) キナゾリン誘導体の塩およびその製造方法
EP3992192B1 (en) Dominant salt forms of pyrimidine derivatives, and crystal forms thereof
WO2016102633A1 (en) Heterocyclic derivatives as rorgamma modulators
WO2024234619A1 (zh) 一种化合物的晶型、药物组合物及用途
JP2026505853A (ja) スルファミド誘導体の結晶形及びその調製方法
CN116323593A (zh) 一种嘧啶衍生物的晶型及其制备方法
HK40030970B (en) Crystal form and salt form of pyridoimidazole compound and preparation method therefor
WO2019120198A1 (zh) 一类喹啉衍生物
HK40030970A (en) Crystal form and salt form of pyridoimidazole compound and preparation method therefor
CN104803877B (zh) 一种o‑苯乙酰‑(4‑三氟甲基)水杨酰胺类化合物及其应用
CN114621113A (zh) 一种化合物及其制备方法和应用
WO2019120199A1 (zh) 一类喹啉衍生物及其生物活性
WO2019120200A1 (zh) 一类喹啉衍生物及其用途
WO2019120202A1 (zh) 一类环己烷类衍生物及其用途
WO2019120201A1 (zh) 一类环己烷类衍生物
HK1193086A1 (en) Mixed crystal agomelatine (form-viii), preparation method and use thereof and pharmaceutical composition containing same
HK1193086B (en) Mixed crystal agomelatine (form-viii), preparation method and use thereof and pharmaceutical composition containing same
HK1174020A (en) Mixed crystal (form-viii) of agomelatine, preparation and use thereof, and pharmaceutical composition containing it